Early Prediction of Preeclampsia Using arteriaL Stiffness in High-risk prEgnancies

Launched by MCGILL UNIVERSITY HEALTH CENTRE/RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE · Mar 1, 2021

Keywords

ClinConnect Summary

This clinical trial, called PULSE, is focused on finding better ways to predict and detect preeclampsia (PE) in women who are at high risk during their pregnancies. Preeclampsia is a serious condition that can lead to severe health issues for both mothers and babies, and it remains a significant cause of maternal deaths worldwide. The study is exploring a non-invasive test that measures arterial stiffness, which can indicate the likelihood of developing high blood pressure issues during pregnancy. By combining this test with blood tests, ultrasound imaging, and health questionnaires, the researchers hope to identify the earliest signs of preeclampsia and improve care for pregnant women.

To be eligible for this trial, participants must be pregnant with only one baby and have at least one factor that puts them at high risk for preeclampsia, or two moderate-risk factors. Unfortunately, women who are more than 14 weeks pregnant, carrying multiples, or have certain health conditions like heart disease or infectious diseases cannot participate. Those who join the study will undergo various tests and assessments to help researchers gather important information about managing and preventing preeclampsia. This trial is currently recruiting participants, and its findings could significantly change how preeclampsia is approached in future pregnancies.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Singleton pregnancy
• • Presence of at least 1 high-risk factor or 2 moderate-risk factors for pre-eclampsia
• Exclusion Criteria:
• • \>14 weeks gestation
• • Multiple pregnancy
• • History of heart disease, stroke, or peripheral arterial disease
• • Infectious diseases/conditions, such as Hepatitis B/C, HIV, and COVID19